52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis-Reference-Cited by-同舟云学术

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis

Published:2017-08-19 Issue:12 Volume:56 Page:2093-2101
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:

Author:

Emery Paul¹²,Vencovský Jiří³,Sylwestrzak Anna⁴,Leszczyński Piotr⁵,Porawska Wieslawa⁶,Baranauskaite Asta⁷,Tseluyko Vira⁸,Zhdan Vyacheslav M.⁹,Stasiuk Barbara¹⁰,Milasiene Roma¹¹,Barrera Rodriguez Aaron Alejandro¹²,Cheong Soo Yeon¹³,Ghil Jeehoon¹³

Affiliation:

1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital

2. Leeds Teaching Hospitals NHS Trust, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK

3. Rheumatology, Institute of Rheumatology, Prague, Czech Republic

4. Rheumatology, NZOZ Medica Pro Familia Sp. z o.o., Warsaw

5. Rheumatology, Poznan University of Medical Sciences, Poznan

6. Rheumatology, Poznanski Osrodek Medyczny NOVAMED, Pultusk, Poland

7. Rheumatology, Lithuanian University of Health Sciences, Kaunas, Lithuania

8. Rheumatology, Kharkiv Medical Academy of Postgraduate Education, Kharkiv

9. Rheumatology, M.V.Sklifosovskyi Poltava Regional Clinical Hospital, Poltava, Ukraine

10. Rheumatology, Medicome Sp. z o.o., Oswiecim, Poland

11. Rheumatology, Klaipeda University Hospital, Klaipeda, Lithuania

12. Rheumatology, Unidad de Atención Medica e Investigación en Salud (UNAMIS), Yucatán, México

13. Medical & Lifecycle Safety, Samsung Bioepis, Incheon, Republic of Korea

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/56/12/2093/24245610/kex269.pdf

Reference30 articles.

1. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution;Kuek;Postgrad Med J,2007

2. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care;Curtis;Clin Ther,2011

3. Biosimilars: a regulatory perspective from America;Kay;Arthritis Res Ther,2011

4. Budget impact analysis of an etanercept biosimilar for the treatment of rheumatoid arthritis in Europe;Ruff;Value Health,2015

5. A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects;Lee;Br J Clin Pharmacol,2016

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study;The Lancet Rheumatology;2024-07

2. Comparative Effectiveness and Persistence of SB4 and Reference Etanercept in Patients With Psoriatic Arthritis in Norway;Arthritis Care & Research;2024-05-29

3. Efficacy of switching from originator etanercept to biosimilar YLB113 in real-world patients with rheumatoid arthritis: A retrospective 12 months follow-up study;Journal of Orthopaedic Surgery;2024-05

4. Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost‐savings;Internal Medicine Journal;2023-11-27

5. Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview;Expert Opinion on Drug Metabolism & Toxicology;2023-10-25